BIOLINERX
Careers | Contact Us
search

Press Releases
December 11, 2018
Results of triple combination arm of BL-8040, KEYTRUDA® and chemotherapy expected in H2 2019
November 20, 2018
Designation provides eligibility for 12 years of market exclusivity that complements robust IP estate

Phase 1/2a study ongoing with topline data expected by year-end 2020

November 1, 2018
Management to hold conference call at 10:00 a.m. EST
October 20, 2018
Results presented today demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment

October 19, 2018
BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer

Encouraging results support further development of combination
and expansion of collaboration

Triple combination expansion cohort (BL-8040 + KEYTRUDA® (pembrolizumab) + chemotherapy) to commence by year-end

October 3, 2018
Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones 

Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter

Management to hold conference call today, October 3, at 10:00 am EDT

1-10  Out of  302
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next